Trial Profile

A prospective, multicentre study to evaluate the efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin in patients with genotype 1 hepatitis C and advanced liver disease in a real-world setting

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
Indications Hepatitis C; Liver disorders
Focus Adverse reactions; Expanded access; Therapeutic Use
Acronyms Rev1tal
Sponsors AbbVie

18 May 2016 New trial record
17 Apr 2016 Preliminary interim analysis (n=172) presented at The International Liver Congress™ 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com